Studies have shown that moderate consumption of red wine benefits health, and investors in biotech company Fluxome Sciences believe the phenomenon should be investigated further, reported financial daily Børsen.
To that end, the company's existing and new investors have put 100 million kroner into harnessing the effects of resveratrol, the compound in red wine that has been hailed as being everything from a cancer preventive to an athletic performance-enhancing stimulant.